Barcelona, July 21, 2022.- Caprabo and the Pasqual Maragall Foundation have renewed their collaboration agreement for the ninth consecutive year, with the aim of promoting research that can help overcome Alzheimer's. Caprabo will continue to support the development of research studies for the prevention of this disease and healthy aging carried out by its research center, the Barcelonaβeta Brain Research Center (BBRC).
Specifically, Caprabo's collaboration with the Pasqual Maragall Foundation is aimed at participants in the Alfa Study, a unique cohort of more than 2,700 people that aims to gather information on the preclinical phase of Alzheimer's in order to understand the natural history of the disease. The volunteers are between 45 and 75 years old and are mostly relatives of people who have already developed Alzheimer's. These volunteers undergo a series of tests, regularly and over decades, to assess cognitive abilities and collect data on their clinical history and lifestyle habits.
The Alfa Study was launched in 2013, thanks to the support of the “la Caixa” Foundation, and is one of the research platforms dedicated to the early detection and prevention of Alzheimer's with the largest number of participants in the world.
Currently, Alzheimer's and dementia are one of the main causes of mortality, disability and dependency. Thus, Alzheimer's disease is responsible for 75% of dementia, chronic health disorders that currently affect more than 900,000 people throughout Spain. That is one in 10 people over 65 years of age, and a third of those over 85. With life expectancy increasing, and if an effective cure is not found to modify its course, by 2050 the number of cases could triple worldwide, exceeding one and a half million people in Spain.
